Dermatology

31-45 of 53

• 

  RestartResume

  Pruritus In PN and AD: Challenge How You Manage Itch

  CME/CE

  Pruritus In PN and AD: Challenge How You Manage Itch

  • 

    

    Peter A. Lio, MD

    Peer

  1.00 credits

• 

  RestartResume

  Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis

  CME/CE

  Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis

  • 

    

    Andrew F. Alexis, MD, MPH

    Peer

  • 

    

    Daniel C. Butler, MD

    Peer

  • 

    

    Shawn G. Kwatra, MD

    Peer

  1.50 credits

• 

  RestartResume

  Psoriasis and Obesity: Going Pound for Pound on Comprehensive, Patient-Centered Management

  CME/CE

  Psoriasis and Obesity: Going Pound for Pound on Comprehensive, Patient-Centered Management

  • 

    

    Jaime Almandoz, MD, MBA, MRCPI, FTOS, DABOM

    Peer

  • 

    

    Daniel C. Butler, MD

    Peer

  • 

    

    Benjamin Ungar, MD

    Peer

  1.00 credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma

  • 

    

    John M. Kirkwood, MD

    Peer

  • 

    

    Paolo A. Ascierto, MD

    Peer

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  1.00 credits 10 episodes

• 

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  MinuteCE®

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  • 

    

    John M. Kirkwood, MD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  MinuteCE®

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  • 

    

    John M. Kirkwood, MD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  1.00 program credits
• advertisement

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  • 

    

    Paolo A. Ascierto, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  • 

    

    Paolo A. Ascierto, MD

    Peer

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  1.00 program credits

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  • 

    

    Paolo A. Ascierto, MD

    Peer

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  1.00 program credits

• 

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  MinuteCE®

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  • 

    

    Paolo A. Ascierto, MD

    Peer

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  1.00 program credits

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  MinuteCE®

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  1.00 program credits
• advertisement

• 

  RestartResume

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  MinuteCE®

  Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma

  • 

    

    Sapna Patel, MD

    Peer

  • 

    

    John M. Kirkwood, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  MinuteCE®

  Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  • 

    

    Paolo A. Ascierto, MD

    Peer

  1.00 program credits

• 

  RestartResume

  No Patient Left Behind! Advancing CKD-Associated Pruritus Care

  CME/CE

  No Patient Left Behind! Advancing CKD-Associated Pruritus Care

  • 

    

    Kieran McCafferty, MD

    Peer

  • 

    

    Maurizio Gallieni, MD

    Peer

  0.25 credits

• Prev
• 1
• 2
• 3
• 4
• Next